- Home
- DRUG vs SDHY Comparison
DRUG vs SDHY Comparison
Compare DRUG & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- SDHY
- Stock Information
- Founded
- DRUG 2019
- SDHY 2020
- Country
- DRUG United States
- SDHY United States
- Employees
- DRUG N/A
- SDHY N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- SDHY Finance/Investors Services
- Sector
- DRUG Health Care
- SDHY Finance
- Exchange
- DRUG Nasdaq
- SDHY Nasdaq
- Market Cap
- DRUG 484.7M
- SDHY 409.6M
- IPO Year
- DRUG N/A
- SDHY N/A
- Fundamental
- Price
- DRUG $69.38
- SDHY $16.54
- Analyst Decision
- DRUG Strong Buy
- SDHY
- Analyst Count
- DRUG 9
- SDHY 0
- Target Price
- DRUG $81.67
- SDHY N/A
- AVG Volume (30 Days)
- DRUG 108.7K
- SDHY 94.0K
- Earning Date
- DRUG 08-11-2025
- SDHY 01-01-0001
- Dividend Yield
- DRUG N/A
- SDHY 8.46%
- EPS Growth
- DRUG N/A
- SDHY N/A
- EPS
- DRUG N/A
- SDHY 1.07
- Revenue
- DRUG N/A
- SDHY N/A
- Revenue This Year
- DRUG N/A
- SDHY N/A
- Revenue Next Year
- DRUG N/A
- SDHY N/A
- P/E Ratio
- DRUG N/A
- SDHY $14.31
- Revenue Growth
- DRUG N/A
- SDHY N/A
- 52 Week Low
- DRUG $23.18
- SDHY $13.93
- 52 Week High
- DRUG $70.23
- SDHY $15.50
- Technical
- Relative Strength Index (RSI)
- DRUG 68.34
- SDHY 38.18
- Support Level
- DRUG $62.21
- SDHY $16.43
- Resistance Level
- DRUG $70.23
- SDHY $16.76
- Average True Range (ATR)
- DRUG 6.00
- SDHY 0.18
- MACD
- DRUG 0.52
- SDHY -0.03
- Stochastic Oscillator
- DRUG 96.01
- SDHY 17.80
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.